Cargando…

Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study

INTRODUCTION: Phosphodiesterase 4 (PDE4), which regulates inflammatory cytokine production leading to atopic dermatitis (AD), is selectively inhibited by difamilast. The objective of this phase III, long-term, open-label study was to evaluate the safety and efficacy of topical difamilast in Japanese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saeki, Hidehisa, Imamura, Tomomi, Yokota, Daisuke, Tsubouchi, Hidetsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276884/ https://www.ncbi.nlm.nih.gov/pubmed/35716332 http://dx.doi.org/10.1007/s13555-022-00751-9

Ejemplares similares

Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double‐blind, vehicle‐controlled trial
por: Saeki, H., et al.
Publicado: (2021)

Difamilast for the treatment of atopic dermatitis
por: Freitas, Egídio, et al.
Publicado: (2023)

Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐ 15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis
por: Saeki, Hidehisa, et al.
Publicado: (2019)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Tacrolimus ointment in the management of atopic dermatitis
por: Baldo, Antonello, et al.
Publicado: (2009)

The Roles of Sex Hormones in the Course of Atopic Dermatitis
por: Kanda, Naoko, et al.
Publicado: (2019)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)
por: Kamiya, Koji, et al.
Publicado: (2022)

A Randomized, Open-Label, Multicenter Trial of Topical Tacrolimus for the Treatment of Pruritis in Patients with Atopic Dermatitis
por: Takeuchi, Satoshi, et al.
Publicado: (2012)

Impact of the Family and Household Environment on Pediatric Atopic Dermatitis in Japan
por: Saeki, Hidehisa, et al.
Publicado: (2023)

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
por: Katoh, Norito, et al.
Publicado: (2022)

Efficacy and safety of topical OPA‐15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double‐blind, placebo‐controlled study
por: Saeki, Hidehisa, et al.
Publicado: (2019)

Anti-Inflammatory Effect of Qingpeng Ointment in Atopic Dermatitis-Like Murine Model
por: Li, Yun-Zhu, et al.
Publicado: (2013)

The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Compound traditional Chinese medicine dermatitis ointment ameliorates inflammatory responses and dysregulation of itch-related molecules in atopic dermatitis
por: Zhang, Rongrong, et al.
Publicado: (2022)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
por: Hagino, Teppei, et al.
Publicado: (2023)

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study
por: Zane, Lee T., et al.
Publicado: (2016)

Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
por: Purohit, Vivek S., et al.
Publicado: (2018)

ORAI1 Genetic Polymorphisms Associated with the Susceptibility of Atopic Dermatitis in Japanese and Taiwanese Populations
por: Chang, Wei-Chiao, et al.
Publicado: (2012)

The Acari Hypothesis, III: Atopic Dermatitis
por: Retzinger, Andrew C., et al.
Publicado: (2022)

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension
por: Cork, M.J., et al.
Publicado: (2019)

Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate‐to‐severe atopic dermatitis: Two‐year data from the ADDRESS‐J disease registry
por: Katoh, Norito, et al.
Publicado: (2022)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2018)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Transient hypogammaglobulinemia and severe atopic dermatitis: Open-label treatment with immunoglobulin in a case series
por: Breslin, Moira E., et al.
Publicado: (2016)

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
por: Cork, Michael J., et al.
Publicado: (2023)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

The ability of biomarkers to assess the severity of atopic dermatitis
por: Nakahara, Takeshi, et al.
Publicado: (2023)

A Case of Darier’s Disease with a Novel Missense Mutation in ATP2A2 Successfully Treated with Calcipotriol/Betamethasone Dipropionate Two-Compound Ointment
por: Hagino, Teppei, et al.
Publicado: (2022)

Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018)

Off-label medications in the treatment of hospitalized children with atopic dermatitis
por: Niedźwiedź, Michał, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b0gg851rnpmdtlompqmi3ih5kk